CIK 0001626644 · Non-accelerated filer<br>Smaller reporting company
Odyssey Health, Inc.
Sign in to watch- Ticker
- ODYY
- Exchange
- OTC
- Industry
- Surgical & Medical Instruments & Apparatus
- FY end
- Jul 31
- Incorporated
- NV
- Entity type
- operating
- EIN
- 471022125
- Phone
- 702-780-6559
- Business address
- 2300 WEST SAHARA AVENUE, SUITE 800-#4012, LAS VEGAS, NV, 89102
- Former names
- Odyssey Group International, Inc.
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2023-01-12 | FARRELL CHRISTINE CFO | Grant or award · Restricted Stock Unit (Right to Buy) | +400,000 | $0.30 | $120K | 1,700,000 |
| 2023-01-12 | Casey Jerome H Director | Grant or award · Restricted Stock Unit (Right to Buy) | +500,000 | $0.30 | $150K | 1,500,000 |
| 2022-11-01 | Gironda Gregory W Chief Operating Officer | Grant or award · Stock Option - Right to buy | +125,000 | $0.25 | $31K | 125,000 |
| 2022-11-01 | Gironda Gregory W Chief Operating Officer | Grant or award · Stock Option - Right to buy | +475,000 | $0.25 | $119K | 0 |
| 2022-11-01 | Emerson Erik C. Chief Commercial Officer | Grant or award · Stock Option - Right to buy | +125,000 | $0.25 | $31K | 125,000 |
| 2022-11-01 | Emerson Erik C. Chief Commercial Officer | Grant or award · Stock Option - Right to buy | +475,000 | $0.25 | $119K | 0 |
| 2022-10-14 | VANLANDINGHAM JACOB PH.D Related Party | Grant or award · Stock Option (Right to Buy) | +1,000,000 | $0.32 | $318K | 2,100,000 |
| 2022-10-14 | FARRELL CHRISTINE Chief Financial Officer | Grant or award · Stock Option (Right to Buy) | +500,000 | $0.32 | $159K | 1,100,000 |
| 2022-09-02 | REDMOND J MICHAEL President & CEO | Gift | −1,500,000 | $0.16 | $245K | 8,500,000 |
| 2022-06-10 | VANLANDINGHAM JACOB PH.D VP of Drug Development | Grant or award | +1,000,000 | $0.23 | $230K | 9,660,000 |
| 2022-05-19 | VANLANDINGHAM JACOB PH.D VP of Drug Development | Grant or award · Stock Option (Right to Buy) | +100,000 | $0.30 | $30K | 1,100,000 |
| 2022-05-19 | RICHARDSON RICKY Director | Grant or award · Stock Option (Right to Buy) | +250,000 | $0.30 | $75K | 750,000 |
| 2022-05-19 | RICHARDSON RICKY Director | Grant or award · Stock Option (Right to Buy) | +250,000 | $0.30 | $75K | 1,000,000 |
| 2022-05-19 | REDMOND J MICHAEL President/CEO | Grant or award · Stock Option (Right to Buy) | +375,000 | $0.30 | $113K | 3,375,000 |
| 2022-05-19 | REDMOND J MICHAEL President/CEO | Grant or award · Stock Option (Right to Buy) | +375,000 | $0.30 | $113K | 3,750,000 |
| 2022-05-19 | GANDOLFO JOHN P Director | Grant or award · Stock Option (Right to Buy) | +250,000 | $0.30 | $75K | 1,250,000 |
| 2022-05-19 | GANDOLFO JOHN P Director | Grant or award · Stock Option (Right to Buy) | +250,000 | $0.30 | $75K | 1,500,000 |
| 2022-05-19 | FARRELL CHRISTINE Chief Financial Officer | Grant or award · Stock Option (Right to Buy) | +300,000 | $0.30 | $90K | 1,300,000 |
| 2022-05-19 | FARRELL CHRISTINE Chief Financial Officer | Grant or award · Stock Option (Right to Buy) | +300,000 | $0.30 | $90K | 1,600,000 |
| 2022-05-19 | Conroy Jeffrey X Director | Grant or award · Stock Option (Right to Buy) | +250,000 | $0.30 | $75K | 1,250,000 |
Page 2 of 3 · 50 trades